argenx Reports Half Year 2025 Financial Results and Business Update

SEC Filing 6-K (0001697862-25-000042)

argenx SE announced its half-year 2025 financial results, reporting $1.74 billion in product net sales, a 98% increase year-over-year. The company highlighted strong growth in its VYVGART franchise, with significant progress in treating patients with severe autoimmune diseases. Key developments include the launch of VYVGART SC prefilled syringe, advancements in clinical trials for efgartigimod, empasiprubart, and ARGX-119, and strategic collaborations to expand its pipeline. The company remains on track with its Vision 2030 goals, aiming to treat 50,000 patients globally and secure 10 labeled indications by 2030.